Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
Introduction: This double-blind, randomized controlled trial compared the safety and efficacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease (ESKD) and anemia who were receiving epoetin a...
Main Authors: | Steven Fishbane, Bruce S. Spinowitz, Wayne A. Wisemandle, Nancy E. Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024919302050 |
Similar Items
-
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
by: Jay B. Wish, et al.
Published: (2019-09-01) -
Epoetin Alfa: A Cause of Coronary Artery Thrombosis
by: Muhammad Umer Siddiqui, et al.
Published: (2017-01-01) -
A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
by: J Wilson, et al.
Published: (2007-04-01) -
Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01) -
Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
by: Amel Harzallah, et al.
Published: (2015-01-01)